A

Aclaris Therapeutics
D

ACRS

1.48000
USD
-0.05
(-2.95%)
مغلق
حجم التداول
0
الربح لكل سهم
-1
العائد الربحي
-
P/E
-1
حجم السوق
160,256,234
أصول ذات صلة
A
ADAP
-0.00030
(-0.12%)
0.24620 USD
A
AGIO
-0.161
(-0.47%)
34.350 USD
A
ALLO
-0.06000
(-4.32%)
1.33000 USD
ALNY
ALNY
3.30
(1.08%)
308.00 USD
AMGN
AMGN
-2.10
(-0.70%)
295.22 USD
A
AMRN
-0.080
(-0.60%)
13.250 USD
A
ARWR
-0.480
(-2.96%)
15.750 USD
A
ASND
-0.230
(-0.13%)
170.680 USD
B
BEAM
-0.355
(-2.04%)
17.055 USD
BMRN
BMRN
-1.000
(-1.75%)
56.220 USD
C
CAPR
-2.150
(-15.45%)
11.770 USD
C
CRSP
0.050
(0.12%)
41.360 USD
E
EDIT
-0.20500
(-9.45%)
1.96500 USD
المزيد
الأخبار المقالات

العنوان: Aclaris Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.